Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Current Deferred Revenue (2021 - 2025)

Core Scientific (CORZW) has disclosed Current Deferred Revenue for 5 consecutive years, with $555.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 2971.0% to $555.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $555.9 million through Dec 2025, up 2971.0% year-over-year, with the annual reading at $555.9 million for FY2025, 2971.0% up from the prior year.
  • Current Deferred Revenue hit $555.9 million in Q4 2025 for Core Scientific, up from $2.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 billion in Q4 2021 to a low of $496000.0 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $165.3 million across 5 years, with a median of $59.6 million in 2024.
  • Biggest five-year swings in Current Deferred Revenue: crashed 99.95% in 2022 and later soared 2971.0% in 2025.
  • Year by year, Current Deferred Revenue stood at $1.0 billion in 2021, then plummeted by 99.95% to $496000.0 in 2022, then surged by 1875.81% to $9.8 million in 2023, then skyrocketed by 84.69% to $18.1 million in 2024, then skyrocketed by 2971.0% to $555.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CORZW at $555.9 million in Q4 2025, $2.5 million in Q3 2025, and $150.1 million in Q2 2025.